A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04487080)
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates, PC - HAL — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (269 Sites)
Showing the first 25 of 269 sites.
- Arizona Oncology Associates, PC - HAL — Goodyear, Arizona
- Yuma Regional Medical Center — Yuma, Arizona
- City of Hope Long Beach Elm — Long Beach, California
- University of California Irvine — Orange, California
- Rocky Mountain Cancer Centers — Lone Tree, Colorado
- Cancer Specialists of North Florida — Jacksonville, Florida
- University Cancer And Blood Center LLC — Athens, Georgia
- East Jefferson General Hospital — Metairie, Louisiana
- Maryland Oncology Hematology, PA — Columbia, Maryland
- Henry Ford Hospital — Detroit, Michigan
- Minnesota Oncology Hematology P A — Edina, Minnesota
- Mayo Clinic — Rochester, Minnesota
- Washington University School Of Medicine — St Louis, Missouri
- Astera Cancer Care — East Brunswick, New Jersey
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- Texas Oncology P A — Austin, Texas
- Oncology Consultants Texas — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Centro Oncológico Korben — Buenos Aires,
- Instituto Alexander Fleming — Buenos Aires,
- Hospital Privado Centro Medico de Cordoba — Córdoba,
- Centro Oncologico Riojano Integral (Cori) — La Rioja,
- Clínica Viedma — Viedma,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.